Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

INTRA-CELLULAR THERAPIES, INC.

(ITCI)
  Report
Delayed Nasdaq  -  04:00:00 2023-02-08 pm EST
48.36 USD   +2.31%
02/08Intra-Cellular Therapies to Present at the SVB Securities Global Biopharma Conference
AQ
01/13RBC Cuts Price Target on Intra-Cellular Therapies to $72 From $74, Maintains Outperform Rating
MT
01/09Intra-cellular Therapies, Inc. : Entry into a Material Definitive Agreement (form 8-K)
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Most relevant news about INTRA-CELLULAR THERAPIES, INC.
02/08Intra-Cellular Therapies to Present at the SVB Securities Global Biopharma Conference
AQ
01/13RBC Cuts Price Target on Intra-Cellular Therapies to $72 From $74, Maintains Outperform..
MT
01/09Transcript : Intra-Cellular Therapies, Inc. Presents at 41st Annual J.P. Morg..
CI
01/03Intra-Cellular Therapies to Present at the 41st Annual J.P. Morgan Healthcare Conferenc..
AQ
2022Insider Sell: Intra-Cellular Therapies
MT
2022Insider Sell: Intra-Cellular Therapies
MT
2022Intra-Cellular Therapies Highlights New CAPLYTA Bipolar Depression Data Presentations a..
AQ
2022Insider Sell: Intra-Cellular Therapies
MT
2022Intra-Cellular Therapies to Participate at Two Upcoming Investor Conferences
AQ
2022RBC Lifts Price Target on Intra-Cellular Therapies to $69 From $67, Maintains Outperfor..
MT
2022Intra-Cellular Therapies Reports Narrower Q3 Loss, Higher Revenue; Shares Jump
MT
2022Transcript : Intra-Cellular Therapies, Inc., Q3 2022 Earnings Call, Nov 03, 2..
CI
2022Intra-cellular : Q3 Earnings Snapshot
AQ
2022Intra-Cellular Therapies, Inc. Reports Earnings Results for the Third Quarter and Nine ..
CI
2022Earnings Flash (ITCI) INTRA-CELLULAR THERAPIES Posts Q3 Revenue $71.9M
MT
2022Intra-Cellular Therapies Reports Third Quarter 2022 Financial Results and Provides Corp..
AQ
2022Intra-Cellular Therapies to Host Third Quarter 2022 Financial Results Conference Call a..
AQ
2022RBC Cuts Price Target on Intra-Cellular Therapies to $67 From $70, Maintains Outperform..
MT
2022Insider Sell: Intra-Cellular Therapies
MT
2022Analyst recommendations: Snowflake, Vipshop, UIta Beauty, VF, Ad..
MS
2022Goldman Sachs Cuts Intra-Cellular Therapies to Neutral From Buy, Price Target to $49 Fr..
MT
2022Insider Sell: Intra-Cellular Therapies
MT
2022Mizuho Securities Adjusts Intra-Cellular Therapies' Price Target to $72 From $75, Keeps..
MT
2022Needham Adjusts Intra-Cellular Therapies' Price Target to $67 from $65, Keeps Buy Ratin..
MT
2022Goldman Sachs Lowers Intra-Cellular Therapies' Price Target to $64 From $71, Maintains ..
MT
2022Intra Cellular Therapies : REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS AND PROVIDES CORP..
PU
2022Transcript : Intra-Cellular Therapies, Inc., Q2 2022 Earnings Call, Aug 09, 2..
CI
2022Intra-Cellular Therapies Q2 Net Loss Widens, Revenue Climbs
MT
2022Intra-cellular : Q2 Earnings Snapshot
AQ
2022Intra-Cellular Therapies Reports Second Quarter 2022 Financial Results and Provides Cor..
AQ
2022Earnings Flash (ITCI) INTRA-CELLULAR THERAPIES Reports Q2 Revenue $55.6M
MT
2022Intra-Cellular Therapies, Inc. Reports Earnings Results for the Second Quarter and Six ..
CI
2022Intra-Cellular Therapies to Host Second Quarter 2022 Financial Results Conference Call ..
AQ
2022Mizuho Securities Initiates Intra-Cellular Therapies at Buy with $75 Price Target
MT
2022RBC Lifts Price Target on Intra-Cellular Therapies to $71 From $70, Maintains Outperfor..
MT
2022Mizuho Initiates Intra-Cellular Therapies With Buy Rating, $75 Price Target, Cites 'Add..
MT
2022UBS Initiates Coverage on Intra-Cellular Therapies With Buy Rating, $75 Price Target
MT
2022Intra-Cellular Therapies Highlights Lumateperone Bipolar Depression Data Presentations ..
AQ
2022Sector Update: Health Care Stocks Carried Higher by Surging Biotechs
MT
2022Sector Update: Health Care Stocks Still Edging Higher This Afternoon
MT
2022Intra-Cellular Therapies Q1 Loss Expands; Revenue Rises; Shares Rise Tuesday Afternoon
MT
2022Intra-Cellular Therapies Q1 Loss Expands; Revenue Rises
MT
2022Transcript : Intra-Cellular Therapies, Inc., Q1 2022 Earnings Call, May 10, 2..
CI
2022Earnings Flash (ITCI) INTRA-CELLULAR THERAPIES Posts Q1 Revenue $35M
MT
2022Intra-cellular : Q1 Earnings Snapshot
AQ
2022Intra-Cellular Therapies Reports First Quarter 2022 Financial Results and Provides Corp..
AQ
2022Intra-Cellular Therapies, Inc. Reports Earnings Results for the First Quarter Ended Mar..
CI
2022Intra-Cellular Therapies to Host First Quarter 2022 Financial Results Conference Call a..
AQ
2022Intra-Cellular Therapies Announces FDA Approval of New Dosage Strengths for CAPLYTA (lu..
AQ
2022Intra-Cellular Therapies Says FDA Approves Two New Dosage Strengths for Treatment of Sc..
MT
2022Intra Cellular Therapies : Announces FDA Approval of New Dosage Strengths for CAPLYTA« (lu..
PU
2022Intra-Cellular Therapies Announces FDA Approval of New Dosage Strengths for CAPLYTA« (l..
AQ
2022Intra-Cellular Therapies, Inc. Announces FDA Approval of New Dosage Strengths for CAPLY..
CI
2022Piper Sandler Starts Intra-Cellular Therapies at Neutral With $59 Price Target
MT
2022SVB Leerink Adjusts Intra-Cellular Therapies Price Target to $70 From $65, Maintains Ou..
MT
2022Intra Cellular Therapies : Announces Appointment of E. Rene Salas to Board of Directors - ..
PU
2022Intra-Cellular Therapies Announces Appointment of E. Rene Salas to Board of Directors
AQ
2022Intra-Cellular Therapies Announces Appointment of E. Rene Salas to Board of Directors a..
CI
2022Insider Sell: Intra-Cellular Therapies
MT
2022RBC Capital Adjusts Intra-Cellular Therapies' Price Target to $70 From $65, Maintains O..
MT
2022Intra-Cellular Therapies to Present at the 21st Annual Needham Virtual Healthcare Confe..
AQ
2022Insider Sell: Intra-Cellular Therapies
MT
2022Certain Option of Intra-Cellular Therapies, Inc. are subject to a Lock-Up Agreement End..
CI
2022Certain Common Stock of Intra-Cellular Therapies, Inc. are subject to a Lock-Up Agreeme..
CI
2022Certain Restricted Stock Unit of Intra-Cellular Therapies, Inc. are subject to a Lock-U..
CI
2022SVB Leerink Adjusts Intra-Cellular Therapies' Price Target to $65 from $50, Keeps Outpe..
MT
2022Transcript : Intra-Cellular Therapies, Inc., Q4 2021 Earnings Call, Mar 01, 2..
CI
2022Intra-Cellular Therapies Widens Q4 Net Loss as Revenue Doubles
MT
2022Intra Cellular Therapies : REPORTS FOURTH QUARTER AND FULL-YEAR 2021 FINANCIAL RESULTS AND..
PU
2022Intra-Cellular Therapies, Inc. Reports Earnings Results for the Fourth Quarter Ended De..
CI
2022Intra-cellular : Q4 Earnings Snapshot
AQ
2022Intra-Cellular Therapies, Inc. Reports Earnings Results for the Full Year Ended Decembe..
CI
2022Earnings Flash (ITCI) INTRA-CELLULAR THERAPIES Posts Q4 Revenue $25.7M
MT
2022Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2021 Financial Results an..
AQ
2022RBC Raises Price Target on Intra-Cellular Therapies to $65 From $55, Maintains Outperfo..
MT
1  2  3  4  5  6  7  8Next
Upcoming event on INTRA-CELLULAR THERAPIES, INC.